Lipella Pharmaceuticals

Lipella Pharmaceuticals Chief Medical Officer Michael Chancellor, discusses the challenges of managing hemorrhagic cystitis, a painful condition marked by lower urinary tract symptoms that poses a critical health challenge in the field of urology. Prism MarketView Q&A: https://bit.ly/3XYJlBj

We are pleased to share early tolerability results in our Phase 2a Trial for Oral Lichen Planus (OLP). Three participants have completed the four-week treatment with LP-310, an oral rinse and have reported the treatment was well tolerated with no unpleasant taste. Currently, there are no FDA-approved pharmacotherapies for Oral Lichen Planus, and LP-310 is the only topical treatment in development for OLP. The clinical trial is expected to conclude by mid-2025, with top-line data anticipated by year-end 2024.?https://bit.ly/4gCMxJT? $LIPO #OLP #clinicaltrials #orallichenplanus #LIPO #positivedata

We're excited to announce that 5 clinical sites are now open for our Phase 2a trial evaluating the safety, tolerability, and efficacy of LP-10 in treating symptomatic Oral Lichen Planus. To find out more, visit:?bit.ly/3z56LLz Lipella Pharmaceuticals #LIPO #OLP #clinicaltrials #OralLichenPlanus

Lipella Pharmaceuticals will be participating at the H.C. Wainwright Conference in New York from September 9th-11th. Please see more details here:?https://bit.ly/471EMc2 #stockstowatch #investors

We're excited to announce the launch of a new registry to advance research on Oral Lichen Planus (OLP). This initiative is focused on increasing awareness and accelerating the search for effective treatments for the millions affected by this challenging condition.? https://bit.ly/4fWHXGk #investors #OLP #pharmaceuticals #clinicaltrial

We are proud to present clinical data on LP-20, our novel MRI contrast agent designed to diagnose interstitial cystitis and detect bladder cancer, at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto,?August 21-23, 2024.?https://bit.ly/3MciIBU #investors #pharmaceuticals

In Case You Missed It: Yesterday we announced exciting news as the first two patients in our Phase 2a trial have been dosed. Read more here from Clinical Trials Arena: Lipella Pharmaceuticals https://bit.ly/4coiQJh

Lipella Pharmaceuticals is pleased to announce the dosing of the first two patients in our Phase 2a clinical trial for Oral Lichen Planus (OLP). Our goal with LP-310 is to address the underlying mechanisms of OLP, aiming for substantial symptom relief and reduced risk of complications.?Our ultimate objective is to bring the first approved drug treatment for Oral Lichen Planus to this underserved patient population. We anticipate receiving top-line data by the end of 2024.? #investors https://bit.ly/3SL8nRs

Our Co-Founder and Chief Medical Officer, Dr. Michael Chancellor was featured in a Q&A by PRISM MarketView to discuss our promising new treatment initiatives for those suffering from Oral Lichen Planus (OLP). Find out more here:?https://bit.ly/3Yo5MAp

Our Co-Founder and Chief Medical Officer, Dr. Michael Chancellor was featured in a Q&A by PRISM MarketView to discuss our promising new treatment initiatives for those suffering from Oral Lichen Planus (OLP). Find out more here:?https://bit.ly/3Yo5MAp